On 7 February, Cristina, Kina, García, Ricard and Pilar (members of the ADIS-Advisory Board), and their supporters, held a second online consultation in the context of our Public Involvement activities. As in the first consultation, this meeting focused on the informed consent process in research projects on Alzheimer’s disease. Members of the Advisory Board provided...Read More

From 31 January to 1 February (Tel Aviv, Israel and online), partners from the ADIS project met for their biannual General Assembly meeting. The “Early Diagnosis of Alzheimer’s Disease by Immune Profiling of Cytotoxic Lymphocytes and Recording of Sleep Disturbances” – short ADIS project – is a JPND-funded 1.3 million EUR three-year project, coordinated by...Read More

On 24 January, Ricard, Pilar, Cristina, Kina and García (members of the ADIS advisory board (ADIS-AB)), and their supporters, met online for their first consultation in the context of Public Involvement activities of the ADIS project. The consultation was hosted by Alzheimer Europe (AE), facilitated by Soraya Moradi-Bachiller (AE Project Officer), and also attended by...Read More

ADIS stands for “Early Diagnosis of Alzheimer‘s Disease by Immune Profiling of Cytotoxic Lymphocytes and Recording of Sleep Disturbances.” The project is funded by the EU Joint Programme for Neurodegenerative Diseases Research (JPND). JPND is the largest global research initiative to address neurodegenerative disease challenges. The ADIS project (start: July 2022) will run for three...Read More

On 14–15 July, the Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) hosted the kick-off meeting of “ADIS” in Sankt Augustin (Germany). ADIS stands for “Early Diagnosis of Alzheimer‘s Disease by Immune Profiling of Cytotoxic Lymphocytes and Recording of Sleep Disturbances”. The project is funded through the EU Joint Programme – Neurodegenerative Disease Research (JPND)....Read More

Biomarkers and algorithms are to enable minimally invasive and cost-effective early diagnosis of Alzheimer‘s disease Alzheimer‘s disease and related dementias are heterogeneous, multifactorial diseases in which several etiopathogenic mechanisms lead to neuronal cell death and loss of cognitive function.  The disease is believed to begin decades before diagnosis, posing a significant treatment challenge. Therefore, the...Read More